Orthobond is a New Jersey surface-technology company that develops proprietary covalently bound antimicrobial nanosurfaces, which kill bacteria, viruses and fungi mechanically — without antibiotics or eluting chemicals — for medical devices and broader applications in commercial, industrial and automotive settings. Its lead product, OSTAGUARD, is an antibacterial coating for implantable devices that received FDA De Novo clearance in 2024 as the first non-drug-eluting antibacterial implant surface treatment, with initial application in spinal implants; the company delivered its first commercial OSTAGUARD-coated implants in January 2025 and reports partnerships across orthopedics, plastic surgery reconstruction, ophthalmology, ENT and dental. Kineticos Life Sciences' AMR Accelerator Fund I invested in 2024 to support the commercialization of the technology.
1
Round
1
Industry
4
Tags
Sep 1, 2026
Latest raise
Funding activity · 1 round
Sep 1, 2026
$8.3M
Debt
Article coming soon.
Pricing
Public hubs orient you on the raise. Paid plans unlock live AI adoption signals across your market.
For individuals and small teams getting started with AI buyer intelligence.
$149
/month
Features
For outbound teams and agencies that need more coverage and faster signal cadence.
$249
/month
Features
Act on this raise
Funding is the starting point. VeilStrat shows whether capital is showing up as hiring, tools, and web activity you can sell into.
